Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 26

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 26
---
 available for our                                                
 current or any future product candidates, which could make it difficult for us to sell profitably, if approved. |

| • | Our business may be adversely affected by economic conditions and current economic weakness. |

| • | Our business may be impacted by political events, war, terrorism, business interruptions and other geopolitical 
 events and uncertainties beyond our control.                                                                    |

| • | We may in the future be unable to retain and recruit qualified scientists, key executives, key employees or key consultants, may delay 
 our development efforts or otherwise harm our business.                                                                                |

| • | Public health crises, such as the COVID-19 pandemic, have had, and could in the future have, a negative 
 effect on our business.                                                                                 |

| • | Our success depends in part on our ability to protect rights in our intellectual property, which cannot 
 be assured.                                                                                             |

| • | We rely on third parties to conduct our preclinical and clinical trials. If these third parties do not                                            
 successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize 
 our product candidates and our business could be substantially harmed.                                                                            |

| • | We rely on third parties to manufacture our product candidates, and we expect to continue to rely on third                                      
 parties for the clinical as well as any future commercial supply of our product candidates and other future product candidates. The development 
 of our current and future product candidates, and the commercialization of any approved products, could be stopped, delayed or made less        
 profitable if any such third party fails to provide us with sufficient clinical or commercial quantities of such product candidates or          
 products, fails to do so at acceptable quality levels or prices or fails to achieve or maintain satisfactory regulatory compliance.             |

| • | We are dependent on third party suppliers, and if we experience problems with any of these third parties, 
 the manufacturing of our product candidates could be delayed, which could harm our results of operations. |

| • | If we cannot meet NASDAQ’s continued listing requirements, NASDAQ may delist our Depositary Shares, 
 which could have an adverse impact on the liquidity and market price of our Depositary Shares.      |

| • | The price of our Depositary Shares may be volatile. |

| • | The liquidity of our Depositary Shares may have an adverse effect on share price. |

| • | Shareholder ownership interests in the Company may be diluted as a result of, among other things, future                  
 financings and